Cargando…

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology

Detalles Bibliográficos
Autores principales:	Vidula, Neelima, Bardia, Aditya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739720/ https://www.ncbi.nlm.nih.gov/pubmed/29290935 http://dx.doi.org/10.18632/oncotarget.22580

Ejemplares similares

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2021)

Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?
por: Panovska, Dena, et al.
Publicado: (2022)

Next frontiers in CAR T-cell therapy
por: Brown, Christine E, et al.
Publicado: (2016)

The Next Frontiers
por: Porcino, Antony
Publicado: (2013)

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2023)

Artificial intelligence for the next generation of precision oncology
por: Ballester, Pedro J., et al.
Publicado: (2021)

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2022)

New Frontiers in Oncological Imaging
por: Zanon, Chiara, et al.
Publicado: (2023)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Editorial: Frontiers in Neuro Oncology and Neurosurgery
por: Altieri, Roberto
Publicado: (2023)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Precision medicine and personalized breast cancer: combination pertuzumab therapy
por: Reynolds, Kerry, et al.
Publicado: (2014)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Proteomics: The Next Frontier—A Biotech Perspective
por: Qoronfleh, M. Walid
Publicado: (2004)

Precision oncology and molecular therapies for hepatocellular carcinoma
por: Chen, Liming, et al.
Publicado: (2022)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

The Next Frontier in Health Geography: Context and Implications for Interventions
por: Curtis, Andrew, et al.
Publicado: (2019)

Point-of-care devices: the next frontier in personalized chemotherapy
por: Borba, Maria Amélia Carlos Souto Maior, et al.
Publicado: (2017)

CJC Pediatric and Congenital Heart Disease: The Next Frontier
por: Harris, Kevin C.
Publicado: (2022)

Frontiers of Oncology: Biobanking Resources for the 21(st )Century
por: Barnholtz-Sloan, Jill, et al.
Publicado: (2011)

Editorial for the Special Issue on “Frontiers of Ultra-Precision Machining”
por: Guo, Jiang, et al.
Publicado: (2022)

Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis
por: Clark, Otávio, et al.
Publicado: (2014)

Pericardial Delivery of Biological Agents: The Next Frontier?
por: Govea, Alayn, et al.
Publicado: (2017)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Stratifying the stratifiers of triple negative breast cancer
por: Wang, Dong-Yu, et al.
Publicado: (2020)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
por: Lloyd, Maxwell R., et al.
Publicado: (2022)

Opioid-free anesthesia: the next frontier in surgical patient safety
por: McLott, Jason, et al.
Publicado: (2022)

RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
por: Morgans, Alicia K., et al.
Publicado: (2011)

The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies
por: Kim, Ted, et al.
Publicado: (2023)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Triple negative breast cancer: A continuing challenge
por: Gupta, Sudeep
Publicado: (2013)

The coming age of data-driven medicine: translational bioinformatics' next frontier
por: Shah, Nigam H, et al.
Publicado: (2012)

Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis
por: Tomcik, Michal
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1q9hit9fnqq9k9lpa9sij93o9g